drugset
drugset / Trial / NCT05835752

The Safety, Tolerability and Pharmacokinetic Study of RAY1225

NCT05835752 ↗

Phase 1 Completed 68 enrolled Guangdong Raynovent Biotech Co., Ltd
RandomizedParallel-groupDouble-blindBasic science

Summary

This trial is conducted in China. The aim of the trial is to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of RAY1225

Timeline

Start
2023-05-18
Primary completion
2024-03-01
Completion
2024-03-23

Drugs

EvaluationDrugModalityDoseRoute
Subject RAY1225 Unknown — Subcutaneous

Indications

obesity disorder